You have read all your free articles, to continue reading subscribe to read the rest of this content.
Norwegian Vaccibody AS announces enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused Already a subscriber Login You have…
Novo Nordisk has announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to Already a subscriber Login You have read all…
Researchers at KTH Royal Institute of Technology are planning a clinical trial of a new treatment for nonalcoholic fatty liver disease and type 2 diabetes which harnesses liver cells’ own ability to burn accumulated fats. In a study involving 86 people with varying degrees of fatty liver diseasAlready a subscriber…
The company's lead human product paclical successfully meets primary objective in pivotal phase III clinical study. The data show that Paclical, which has orphan designation for epithelial ovarian cancer in the EU and in the US, met the pre-defined requirement of non-inferiority compared with TaxAlready a subscriber Login You have…
